MEN-ACYW135

MEN-ACYW135 refers to an investigational vaccination strategy involving the reduced-dose intradermal administration of quadrivalent meningococcal conjugate vaccines. This approach, evaluated in clinical trials (such as NCT01782066) led by Leiden University Medical Center, utilizes fractional doses (1/5th or 1/10th) of established vaccines like Menveo (conjugated to CRM197) and Nimenrix (conjugated to tetanus toxoid). By targeting the dermis, which is rich in antigen-presenting cells, the strategy aims to elicit a robust immune response comparable to standard intramuscular administration while significantly reducing costs and increasing vaccine availability in low-resource settings. The vaccines provide protection against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.

Brand names

MenveoNimenrix

Other names

MEN-ACYW135-Leiden University Medical Center-meningococcal diseaseMEN-ACYW-135-Leiden University Medical Center-meningococcal diseaseMEN-ACYW 135-Leiden University Medical Center-meningococcal diseaseMEN-ACYW135 reduced-dose intradermal administrationMEN-ACYW-135 reduced-dose intradermal administrationMEN-ACYW 135 reduced-dose intradermal administrationReduced-dose intradermal MenACWY